Clinical trial
A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS
NCT04322149 is registered in ClinicalTrials.gov with Anelixis Therapeutics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS
- Lead sponsor
- Anelixis Therapeutics, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 16, 2020
- Completion date
- March 24, 2022
- Enrollment
- 54 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.